| Autor: |
Huggar D; Bristol Myers Squibb, Princeton, NJ 08540, USA., Knoth RL; Bristol Myers Squibb, Princeton, NJ 08540, USA., Copher R; Bristol Myers Squibb, Princeton, NJ 08540, USA., Cao Z; Premier Inc., Charlotte, NC 28277, USA., Lipkin C; Premier Inc., Charlotte, NC 28277, USA., McBride A; Bristol Myers Squibb, Summit, NJ 07901, USA., LeBlanc TW; Duke University School of Medicine, Durham, NC 27705, USA. |
| Abstrakt: |
Aim: This retrospective, observational study assessed healthcare resource utilization (HCRU) and costs for newly diagnosed acute myeloid leukemia (AML) patients receiving intensive induction chemotherapy. Materials & methods: Adult AML patients with inpatient hospitalization or hospital-based outpatient visit receiving intensive induction chemotherapy (CPX-351 or 7 + 3 treatments) were identified from the Premier Healthcare Database (US). Results: All 642 patients had inpatient hospitalizations (median number = 2; median length of stay = 16 days); 22.4% had an ICU admission. Median total outpatient hospital cost was US$2904 per patient, inpatient hospital cost was $83,440 per patient, and ICU cost was $16,550 per patient. Discussion: In the US hospital setting, substantial HCRU and costs associated with intensive induction chemotherapy for AML were driven by inpatient hospitalizations. |
